Drugs / TQB3702
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06448273 | Jul → Oct 2024 | systemic lupus erythematosus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT06211751 | Jan 2024 → Dec 2025 | hematopoietic and lymphoid cell neoplasm | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05610202 | Nov 2022 → Aug 2024 | hematopoietic and lymphoid cell neoplasm | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06859931 | Mar 2025 → Dec 2026 expected | systemic lupus erythematosus | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06566586 | Nov 2024 → Mar 2026 overdue | B-cell non-Hodgkin lymphoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQB3702 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06859931 ↗ |
| Action | Inhibit | “TQB3702 tablets are selective BTK inhibitors.” NCT05610202 ↗ |
| Route | Oral | “TQB3702 tablets were administered orally” NCT05610202 ↗ |
| Target | BTK | “TQB3702 tablets are selective BTK inhibitors.” NCT05610202 ↗ |